| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $94.19B | $88.82B | $85.16B | $79.99B | $78.74B | $82.58B | $82.06B | $81.58B |
| Cost of Revenue | $25.64B | $27.47B | $26.55B | $24.60B | $23.40B | $28.43B | $27.56B | $27.09B |
| Gross Profit | $68.56B | $61.35B | $58.61B | $55.39B | $55.34B | $54.16B | $54.50B | $54.49B |
| Gross Margin | 72.78% | 69.07% | 68.82% | 69.25% | 70.28% | 65.58% | 66.42% | 66.79% |
| Operating Expenses | $42.96B | $39.20B | $35.20B | $34.38B | $34.40B | $34.42B | $33.53B | $33.31B |
| Operating Income | $25.60B | $22.15B | $23.41B | $21.01B | $20.94B | $19.73B | $20.97B | $21.18B |
| Operating Margin | 27.17% | 24.94% | 27.49% | 26.27% | 26.60% | 23.89% | 25.55% | 25.96% |
| Net Income | $26.80B | $14.07B | $35.15B | $17.94B | $20.88B | $14.71B | $15.12B | $15.30B |
| Net Margin | 28.46% | 15.84% | 41.28% | 22.43% | 26.52% | 17.82% | 18.42% | 18.75% |
| EPS (Basic) | $0.00 | $5.84 | $13.88 | $6.83 | $7.93 | $5.59 | $5.74 | $5.75 |
| EBITDA | N/A | $24.78B | $23.32B | $26.61B | $26.75B | $23.93B | $24.66B | $25.93B |
| Stock Option Compensation Expense | N/A | $1.18B | $1.16B | $1.14B | $1.14B | $1.00B | $977.00M | $978.00M |
| Price To Earnings Ratio | N/A | 24.53 | 11.30 | 25.73 | 21.54 | 28.16 | 25.40 | 22.46 |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | $345.06B | $397.10B | $461.69B | $449.74B | $414.30B | $384.00B | $343.57B |
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Short Term Receivables | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Inventories | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Property, Plant & Equipment | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Investments and Advances | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long-Term Note Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Intangible Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Assets | $0.00 | $180.10B | $167.56B | $187.38B | $182.02B | $174.89B | $157.73B | $152.95B |
| Short Term Debt Incl. Current Port. of LT Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Provision for Risks Charges | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $0.00 | $108.61B | $98.78B | $110.57B | $108.00B | $111.62B | $98.26B | $93.20B |
| Non-Equity Reserves | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Stock - Carrying Value | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Common Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Shareholders Equity | $0.00 | $71.49B | $68.77B | $76.80B | $74.02B | $63.28B | $59.47B | $59.75B |
| Accumulated Minority Interest | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $0.00 | $71.49B | $68.77B | $76.80B | $74.02B | $63.28B | $59.47B | $59.75B |
| Total Liabilities & Stockholders Equity | $0.00 | $180.10B | $167.56B | $187.38B | $182.02B | $174.89B | $157.73B | $152.95B |
| Book Value Per Share | N/A | $29.70 | $27.15 | $29.39 | $28.16 | $24.04 | $22.59 | $22.44 |
| Tangible Book Value Per Share | N/A | $-4.29 | $-0.77 | $0.87 | $-2.90 | $-10.07 | $-8.29 | $-6.88 |
| Full-Time Employees | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Book Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | 7.81% | 20.98% | 9.57% | 11.47% | 8.41% | 9.59% | 10.00% |
| Return on Equity | N/A | 19.68% | 51.11% | 23.36% | 28.20% | 23.25% | 25.42% | 25.60% |
| Return on Invested Capital | N/A | 13.75% | 16.61% | 12.31% | 13.83% | 13.03% | 14.88% | 14.45% |
| Quick Ratio | N/A | 0.86 | 0.91 | 0.81 | 1.12 | 0.99 | 1.01 | 1.20 |
| Current Ratio | N/A | 1.11 | 1.16 | 0.99 | 1.35 | 1.21 | 1.26 | 1.47 |
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $26.80B | $14.07B | $35.15B | $17.94B | $20.88B | $14.71B | $15.12B | $15.30B |
| Depreciation | N/A | $7.34B | $7.49B | $6.97B | $7.39B | $7.23B | $7.01B | $6.93B |
| Other Funds (Non Cash) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Funds from Operations | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Extraordinary Item | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Changes in Working Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Taxes Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Operating Activities | $0.00 | $24.27B | $22.79B | $21.19B | $23.41B | $23.54B | $23.42B | $22.20B |
| Capital Expenditures | N/A | $4.42B | $4.54B | $4.01B | $3.65B | $3.35B | $3.50B | $3.67B |
| Net Assets From Acquisitions | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Fixed Assets and Businesses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase or Sale of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale Or Maturity of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Sources | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Investing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash Dividends Paid | N/A | $11.82B | $11.77B | $11.68B | $11.03B | $10.48B | $9.92B | $9.49B |
| Change in Capital Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Repurchase of Common Pref Stock | N/A | $2.43B | $5.05B | $6.04B | $3.46B | $3.22B | $6.75B | $5.87B |
| Sale of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Proceeds from Stock Options | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance or Reduction of Debt, Net | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Reduction of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Financing Active Other Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Financing Activities Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Financing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Exchange Rate Effect | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Change in Cash | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | $19.84B | $18.25B | $17.18B | $19.76B | $20.19B | $19.92B | $18.53B |
| Preferred Dividends (Cash Flow) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Company coverage
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Why it moved over time
Stock moved after Johnson & Johnson agreed to an uncapped $5.5 billion talc settlement resolving claims from about 70,000 plaintiffs, ending decades of litigation and trial losses.
Key fact: Agreed to an uncapped $5.5 billion talc settlement resolving claims from ~70,000 plaintiffs.
The Motley Fool: Johnson & Johnson vs. Eli Lilly: Reliable Stability vs. Rapid Revenue Growth